I. A. Asangani

NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis

This study identifies NSD2 as a critical component of the AR neo-enhanceosome in prostate cancer, showing its role in AR enhancer circuitry and tumor progression.

Physiological reprogramming in vivo mediated by Sox4 pioneer factor activity

This study shows Sox4 initiates hepatobiliary metaplasia by first closing hepatocyte enhancers and then opening biliary enhancers in adult liver cells.

Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling

This study shows that SETD2 inactivation in lung adenocarcinoma leads to increased oxidative metabolism and mTORC1 activity, making these tumors sensitive to inhibitors of oxidative respiration and mTORC1.

Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1

The paper identifies a 32-gene signature specific to Ewing sarcoma and shows that LOXHD1, a stereociliary protein, is a key driver of malignancy through its regulation by EWSR1-FLI1.

Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer

This study identifies thymidylate synthase (TS) as a driver of epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC), linking it to metastasis, chemotherapy resistance, and survival.

Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers

This study shows that thymidylate synthase promotes de-differentiation in aggressive breast cancers by supporting pyrimidine catabolism and EMT, correlating with poor prognosis.